title: Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab.
abstract: Reported herein is a case of relapse of nephrotic syndrome (NS) after intravitreal injection of bevacizumab, a monoclonal antibody that binds to vascular endothelial growth factor (VEGF), in a 16-year-old girl. She had a diagnosis of steroid-dependent NS and had been treated with prednisolone, and remained in remission. The patient had had visus brevior 10 years previously, and was diagnosed with severe myopic choroidal neovascularization (mCNV). Intravitreal bevacizumab was given for mCNV. At 9 days after intravitreal injection of bevacizumab, proteinuria was positive. The patient had relapse of NS caused by bevacizumab, and steroid pulse therapy was then given and the proteinuria resolved. It is necessary to take particular care to prevent NS relapses in patients with mCNV treated with intravitreal bevacizumab.
authors.affiliation: Department of Pediatrics, Jusendo General Hospital, Fukushima, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Sato
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Waragai
authors.forename: Tomoko
authors.initials: T
authors.lastname: Imaizumi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ono
authors.forename: Nobuko
authors.initials: N
authors.lastname: Sakai
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Hosoya
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D009216:Myopia / Q000150:complications; D009402:Nephrosis, Lipoid / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D011239:Prednisolone